...
Use case provider ordering from laboratory
actor EHR-s uses CPOE and then LOI to create and send orders
if applicable: HIE must receive LOI, perform any transformations / translations and send the modified order using LOI
actor LIS receives and validates LOI order
Use case laboratory ordering from reference laboratory (which could be a PHL or a bloodbank, too)
actor LIS uses CPOE and then LOI to create and send orders
if applicable: HIE must receive LOI, perform any transformations / translations and send the modified order using LOI
actor LIS receives and validates LOI order
If intent is to support use of LRI for results coming back after electronic ordering, then
Use laboratory sends results to ordering provider
actor LIS creates result(s) and uses LRI to send result(s)
if applicable: HIE must receive LRI, perform any transformations / translations and send the modified order using LRI
actor EHR-s receives and validates LRI result(s)
Use case laboratory receiving results from reference laboratory
actor LIS creates result(s) and uses LRI to send result(s)
if applicable: HIE must receive LRI, perform any transformations / translations and send the modified order using LRI
actor LIS receives and validates LRI result(s)
Intermediary Use (HIE): For HIEs to be certified HIT, there should be a requirement that no relevant content is lost (like specimen details or AOEs at the data element level or at the content level when mappings are not equivalent)
#3 Postpone Use of In regards to § 170.315(f)(4) and § 170.315(f)(24) we suggest to postpone the use of the FHIR Cancer Pathology Reporting IG (https://hl7.org/fhir/us/cancer-reporting/ ) in HTI-2 as there is not currently FHIR capability in the US labortaory data exchange and request use of NAACCR instead request to list the V2.5.1 IG <ADD LINK HERE>based NAACCR IG (https://www.naaccr.org/wp-content/uploads/2024/04/NAACCR-EPath-Reporting-guide_v51_Revised_20240328.pdf), which is widely implemented for reporting to cancer registries.
...